Nan Niu Selected Research

Therapeutics

11/2023	CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer.
1/2023	KK-LC-1 as a therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer.
1/2023	Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer.
1/2023	Efficacy and safety of endocrine therapy after mastectomy in patients with hormone receptor positive breast ductal carcinoma in situ: Retrospective cohort study.
11/2022	A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer.
11/2022	Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy.
1/2022	Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model.
1/2021	Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells.
3/2020	Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nan Niu Research Topics

Disease

12	Neoplasms (Cancer) 02/2024 - 01/2019
10	Adenocarcinoma 02/2024 - 01/2020
6	Breast Neoplasms (Breast Cancer) 03/2024 - 01/2022
6	Pancreatic Neoplasms (Pancreatic Cancer) 02/2024 - 03/2020
4	Hypoxia (Hypoxemia) 11/2023 - 03/2019
2	Atherosclerosis 01/2024 - 08/2015
2	Triple Negative Breast Neoplasms 12/2023 - 01/2023
2	Myocardial Infarction 11/2023 - 08/2015
2	Stomach Neoplasms (Stomach Cancer) 01/2020 - 01/2019
2	Cardiovascular Diseases (Cardiovascular Disease) 11/2018 - 08/2016
2	Acute Coronary Syndrome 08/2016 - 08/2015
1	Bites and Stings (Sting) 11/2023
1	Breast Ductal Carcinoma 01/2023
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2023
1	Carotid Artery Diseases 01/2023
1	Atherosclerotic Plaque (Atheroma) 01/2023
1	Mastitis 01/2023
1	Neoplasm Metastasis (Metastasis) 11/2022
1	Cholangiocarcinoma 01/2022
1	B-Cell Lymphoma (Lymphoma, B Cell) 08/2021
1	Mitochondrial Diseases (Mitochondrial Disease) 03/2019
1	Inflammation (Inflammations) 01/2019
1	Coinfection 06/2016
1	Ataxia Telangiectasia (Louis Bar Syndrome) 05/2016
1	Laryngeal Neoplasms (Laryngeal Cancer) 05/2016
1	Pain (Aches) 04/2016
1	Hyperalgesia 04/2016

Drug/Important Bio-Agent (IBA)

3	Letrozole (Femara)FDA LinkGeneric 03/2024 - 11/2022
3	pyrotinibIBA 03/2024 - 11/2022
3	dalpiciclibIBA 03/2024 - 11/2022
3	Proteins (Proteins, Gene)FDA Link 05/2023 - 05/2016
3	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2020
3	InflammasomesIBA 01/2023 - 08/2015
2	Caspase 3 (Caspase-3)IBA 11/2023 - 08/2021
2	CytokinesIBA 11/2023 - 01/2022
2	Focal Adhesion Protein-Tyrosine KinasesIBA 11/2022 - 01/2021
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2022
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 10/2020 - 03/2020
1	pertuzumabIBA 03/2024
1	Trastuzumab (Herceptin)FDA Link 03/2024
1	olaparibIBA 01/2024
1	Eosine Yellowish-(YS) (Eosin)IBA 11/2023
1	ImmunosorbentsIBA 11/2023
1	Hematoxylin (Haematoxylon)IBA 11/2023
1	EnzymesIBA 11/2023
1	Indicators and Reagents (Reagents)IBA 05/2023
1	Estrogens (Estrogen)FDA Link 01/2023
1	Drug CombinationsIBA 01/2023
1	Tamoxifen FDA LinkGeneric 01/2023
1	Hormones (Hormone)IBA 01/2023
1	Aldehyde Dehydrogenase 1 FamilyIBA 01/2023
1	Z 008IBA 01/2023
1	Therapeutic UsesIBA 01/2023
1	Hyaluronoglucosaminidase (Hyaluronidase)FDA Link 11/2022
1	Hyaluronic Acid (Hyaluronan)IBA 11/2022
1	Programmed Cell Death 1 ReceptorIBA 11/2022
1	PEGPH20IBA 11/2022
1	AntigensIBA 10/2022
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 10/2022
1	ChromatinIBA 10/2022
1	Long Noncoding RNAIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Nuclear RNAIBA 01/2022
1	Granzymes (Granzyme)IBA 01/2022
1	bcl-2-Associated X Protein (bcl 2 Associated X Protein)IBA 08/2021
1	Matrix Metalloproteinases (MMPs)IBA 08/2021
1	Nuclear Respiratory Factor 1IBA 08/2021
1	Caspase 8 (Caspase-8)IBA 08/2021
1	CaspasesIBA 08/2021
1	Death Domain ReceptorsIBA 08/2021
1	Caspase 9IBA 08/2021
1	Cytochromes c (Cytochrome c)IBA 08/2021
1	Cancer VaccinesIBA 10/2020
1	IpilimumabIBA 10/2020
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 03/2020
1	InterferonsIBA 03/2020
1	VaccinesIBA 03/2020
1	Peptide Hydrolases (Proteases)FDA Link 01/2020
1	Serine (L-Serine)FDA Link 01/2020
1	MicroRNAs (MicroRNA)IBA 01/2020
1	cobaltous chloride (cobalt(II)chloride)IBA 03/2019
1	Uric Acid (Urate)IBA 01/2019
1	Macrophage Migration-Inhibitory FactorsIBA 01/2019
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2019
1	AngiotensinogenIBA 11/2018
1	Toll-Like Receptor 4IBA 11/2018
1	omega-Chloroacetophenone (Mace)IBA 08/2016
1	AntibodiesIBA 06/2016
1	Recombinant ProteinsIBA 06/2016
1	sodium glycididazoleIBA 05/2016
1	Fentanyl (Sublimaze)FDA LinkGeneric 04/2016

Therapy/Procedure

9	Therapeutics 11/2023 - 03/2020
4	Drug Therapy (Chemotherapy) 03/2024 - 03/2020
2	Radiotherapy 02/2024 - 01/2021
2	Immunotherapy 01/2022 - 03/2020
1	Neoadjuvant Therapy 03/2024
1	Radioimmunotherapy 02/2024
1	Mastectomy (Mammectomy) 01/2023
1	Adjuvant Chemotherapy 01/2022
1	Pancreaticoduodenectomy 01/2020